Skip to main content
Midas Edge

Quanterix Corp

For the period ended Dec 31, 2025. Filed Mar 2, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 2, 2026

QTRX$3.28-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits and Financial Statement Schedules

(1)Financial Statements

The Consolidated Financial Statements are included beginning on page F-1 attached hereto and are filed as part of this Annual Report on Form 10-K.

(2)Financial Statement Schedules

Financial statement schedules have been omitted since they either are not required, not applicable, or the information is otherwise included.

(3)Exhibits

The following is a list of exhibits filed as part of this Annual Report on Form 10-K:

Exhibit Number · Exhibit Description · FiledHerewith · Incorporated byReference herein fromForm or Schedule · Filing Date · SEC File/Reg. Number
2.1@Share Purchase Agreement, dated December 16, 2024, by and among Quanterix Corporation, Emission Inc., the Shareholders of Emission Inc. and the Shareholder Representative8-K12/17/2024001-38319
2.2#Amended and Restated Agreement and Plan of Merger, dated March 28, 2025, by and among the Registrant, Wellfleet Merger Sub, Inc., and Akoya Biosciences, Inc.8-K4/29/2025001-38319
3.1Amended and Restated Certificate of Incorporation8-K10/2/2025001-38319
3.2Restated Bylaws8-K10/2/2025001-38319
4.1Description of Securities10-K3/13/2020001-38319
4.2Form of Common Stock CertificateS-111/9/2017333-221475
10.1.1+2007 Stock Option and Grant Plan, as amendedS-111/9/2017333-221475
10.1.2+Form of Incentive Stock Option Agreement under the 2007 Stock Option and Grant Plan, as amendedS-111/9/2017333-221475
10.1.3+Form of Non-qualified Stock Option Agreement under the 2007 Stock Option and Grant Plan, as amendedS-111/9/2017333-221475
10.1.4+Form of Restricted Stock Agreement under the 2007 Stock Option and Grant Plan, as amendedS-111/9/2017333-221475
10.2.1+2017 Employee, Director and Consultant Equity Incentive PlanS-1/A11/27/2017333-221475
Exhibit NumberExhibit DescriptionFiledHerewithIncorporated byReference herein fromForm or ScheduleFiling DateSEC File/Reg. Number
10.2.2+Form of Stock Option Agreement under the 2017 Employee, Director and Consultant Equity Incentive PlanS-1/A11/27/2017333-221475
10.2.3+Form of Restricted Stock Agreement under the 2017 Employee, Director and Consultant Equity Incentive PlanS-1/A11/27/2017333-221475
10.2.4+Form of Restricted Stock Unit Agreement under the 2017 Employee, Director and Consultant Equity Incentive Plan10-K2/29/2024001-30319
10.3.1+Akoya Biosciences, Inc. 2021 Equity Incentive Plan and form of stock option agreement thereunderS-1/A4/12/2021333-254760
10.3.2+Akoya Biosciences, Inc. Form of Indemnification Agreement8-K12/13/2024001-40344
10.4.1+Amended and Restated 2025 Inducement PlanS-81/15/2026333-292362
10.4.2+Form of Stock Option Agreement under the 2025 Inducement PlanS-812/22/2025333-292362
10.4.3+Form of Restricted Stock Unit Agreement under the 2025 Inducement PlanS-812/22/2025333-292362
10.5.1+Employment Agreement, dated August 3, 2023, between the Registrant and Vandana Sriram8-K8/9/2023001-38319
10.5.2+Amendment, effective as of April 11, 2024, to the Employment Agreement, dated August 3, 2023, between the Registrant and Vandana Sriram8-K4/12/2024001-38319
10.7.1+Amended and Restated Employment Agreement, dated April 25, 2022, between the Registrant and Dr. Masoud Toloue8-K4/29/2022001-38319
10.7.2+Amendment, dated April 9, 2024, to the Amended and Restated Employment Agreement, dated April 25, 2022, between the Registrant and Dr. Masoud Toloue8-K4/12/2024001-38319
10.7.3+Separation Agreement by and between the Company and Masoud Toloue8-K1/8/2026001-38319
10.8+Employment Agreement by and between the Company and William DonnellyX
10.9+Employment Agreement by and between the Company and Everett Cunningham8-K1/8/2026001-38319
Exhibit NumberExhibit DescriptionFiledHerewithIncorporated byReference herein fromForm or ScheduleFiling DateSEC File/Reg. Number
10.10.1*Exclusive License Agreement, dated June 18, 2007, between the Registrant and Tufts University, as amended on April 29, 2013S-111/9/2017333-221475
10.10.2*Second Amendment, dated August 22, 2017, to the Exclusive License Agreement between the Registrant and Tufts UniversityS-111/9/2017333-221475
10.10.3@Third Amendment, dated September 25, 2020, to the Exclusive License Agreement between the Registrant and Tufts University10-Q11/6/2020001-38319
10.11.1*Supply and Manufacturing Agreement, dated September 14, 2011, between the Registrant and STRATEC Biomedical AGS-111/9/2017333-221475
10.11.2First Amendment to Supply and Manufacturing Agreement, dated October 17, 2013, between the Registrant and STRATEC Biomedical AGS-111/9/2017333-221475
10.12.1*STRATEC Development Services and Equity Participation Agreement, dated August 15, 2011, between the Registrant and STRATEC Biomedical Systems AGS-111/9/2017333-221475
10.12.2*First Amendment to STRATEC Development Services and Equity Participation Agreement and Second Amendment to Supply and Manufacturing Agreement, dated November 18, 2016, between the Registrant and STRATEC Biomedical AGS-111/9/2017333-221475
10.13@Third Amendment to Supply and Manufacturing Agreement, entered into on June 17, 2025 and effective as of January 1, 2025 between the Registrant and STRATEC SE10-Q8/7/2025001-38319
10.14*Manufacturing Services Agreement, dated November 23, 2016, between the Registrant and Paramit CorporationS-111/9/2017333-221475
10.15*Exclusivity (Equity) Agreement, dated November 17, 2015, by and between Akoya Biosciences, Inc. and The Board of Trustees of the Leland Stanford Junior UniversityS-13/26/2021333-254760
10.16*Amendment No. 1 to the License Agreement, dated November 18, 2016, by and between Akoya Biosciences, Inc. and the Board of Trustees of the Leland Stanford Junior UniversityS-13/26/2021333-254760
10.17*Manufacturing Agreement, dated July 17, 2019 between Akoya Biosciences, Inc. and Columbia Electrical Contractors, Inc.X
Exhibit NumberExhibit DescriptionFiledHerewithIncorporated byReference herein fromForm or ScheduleFiling DateSEC File/Reg. Number
10.18*License and Royalty Agreement, dated September 28, 2018, by and among Akoya Biosciences, Inc., PerkinElmer Health Services, Inc., Cambridge Research and Instrumentation, Inc., and VisEn Medical Inc.S-13/26/2021333-254760
10.19*Exclusive Patent License Agreement, dated June 26, 2018, by and between Akoya Biosciences, Inc. and the University of WashingtonS-13/26/2021333-254760
10.20Cooperation Agreement, by and between Quanterix Corporation, Kent Lake PR LLC and Kent Lake Partners LP, dated August 4, 20258-K8/4/2024001-38319
10.21+Form of Indemnification AgreementS-1/A11/27/2017333-221475
10.22Lease Agreement by and between SSI 900 Middlesex MA LP and the Registrant, dated October 2, 20188-K10/5/2018001-38319
10.23Lease Agreement by and between the Registrant and XChange Owner LLC, dated January 28, 20228-K1/31/2022001-38319
10.24+Amended and Restated Non-Employee Director Compensation PolicyX
10.25.1#Voting and Support Agreement, dated April 28, 2025, by and among the Registrant and certain stockholders of Akoya Biosciences, Inc. named therein.8-K4/29/2025001-38319
10.25.2*Consent and Waiver under the Voting and Support Agreement, dated April 28, 2025, by and among the Registrant and certain stockholders of Akoya Biosciences, Inc. named therein8-K4/29/2025001-38319
10.26.1Securities Purchase Agreement between the Registrant and Akoya Biosciences, Inc. dated April 2, 20258-K4/4/2025001-38319
10.26.2Amendment No. 1, dated April 28, 2025, to the Securities Purchase Agreement between the Registrant and Akoya Biosciences, Inc. dated April 2, 20258-K4/29/2025001-38319
19.1Quanterix Insider Trading PolicyX
21.1Subsidiaries of RegistrantX
23.1Consent of KPMG LLPX
23.2Consent of Ernst & Young LLPX
Exhibit NumberExhibit DescriptionFiledHerewithIncorporated byReference herein fromForm or ScheduleFiling DateSEC File/Reg. Number
31.1 · Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 · X
31.2 · Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 · X
32.1 · Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 · X
97.1Policy relating to recovery of erroneously awarded compensation10-K2/29/2024001-38319
101.INSInline XBRL Instance DocumentX
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Extension DefinitionX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX
101.PREInline XBRL Taxonomy Presentation Linkbase DocumentX
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Management contract or compensatory plan or arrangement.
*Confidential treatment has been granted for portions of this Exhibit. Redacted portions have been filed separately with the SEC.
@Portions of this document (indicated by "[***]") have been omitted because such information is not material and is the type of information that the Registrant treats as private or confidential.
#Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant hereby undertakes to furnish supplemental copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the Registrant may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any exhibits or schedules so furnished.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.